Chen Wei, an academician of China’s Academy of Engineering and a researcher at the Academy of Military Sciences, revealed at the 2021 Pujiang Innovation Forum held in Shanghai on June 3 that her team, in conjunction with vaccine maker CanSino Biologics, has developed an inhalant Covid-19 vaccine and is applying to Chinese authorities for emergency use approval.
The Convidecia nasal spray vaccine, based on CanSino’s recombinant coronavirus vaccine, is administered through the nose by spray inhalation. It only uses one-fifth of the dose of a regular vaccine and does not need to be stored in special bottles or ultra-low temperatures. Clinical trial results indicated the vaccine produces an immune response in three days.
Chen did not reveal when the inhalent vaccine will be officially used. Analysts predicted the fastest rollout time would be in July, as it usually takes the authorities one month to approve a vaccine.
Old Version
